The transplant diagnosis market value is expected to reach USD 7.42 Billion at 7.8% CAGR by 2030.
The transplant diagnostics market is anticipated to grow at high speed in the years to come. The transplant diagnosis market value is expected to reach USD 7.42 Billion over the forecast period, with a CAGR (Compound Annual Growth Rate) of about 7.8% by 2030. This is because of increasing technological advancements in medical devices and the rising number of organic failures among the global population.
The increasing adoption of transplant diagnostics is mainly because of the rising prevalence of chronic diseases across the globe. The expanding funding for research & development institutes will also help strengthen the global market during the forecast period. Moreover, the escalating senior population is likely to boost the transplant diagnostics market value. Conversely, the high expenditures related to PCR and NGS devices will probably inhibit the market growth over the forecast period.The market has witnessed substantial investments from major medical institutions. In May 2022, the National Institutes of Health (NIH) said that they had allocated USD 208 million in 2020 and USD 201 million in 2021 on organ transplant research. Due to the increasing use of transplant diagnostics in the scientific community, the abundance of funding for solid organ transplantation is a key factor in the sector's continued expansion.
With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The transplantation diagnosis market saw a slight downfall post the pandemic due to the lockdown and physical distancing.
The pandemic has severely hindered the market growth, which has affected the forecast market value significantly. However, the pandemic situation is expected to wear off in the coming years. Hence, the market will see a steady growth in the forecast years.Despite the pandemic, the market continued to evolve owing to active key players. For instance, in August 2021 Natera, Inc., a pioneer in the field of transforming care using genetic and cell-free DNA (cfDNA) testing, announced the validation and clinical availability of its Prospera Heart transplant evaluation test for heart transplant recipients. This launch capitalizes on Natera's experience conducting over 3 million cfDNA testing around the world, and it is the first large application of the Prospera technology outside of kidney transplant.Despite the pandemic, the market continued to evolve owing to active key players. For instance, in August 2021 Natera, Inc., a pioneer in the field of transforming care using genetic and cell-free DNA (cfDNA) testing, announced the validation and clinical availability of its Prospera Heart transplant evaluation test for heart transplant recipients. This launch capitalizes on Natera's experience conducting over 3 million cfDNA testing around the world, and it is the first large application of the Prospera technology outside of kidney transplant.
A few factors may drive the growth of the transplant diagnostics market share. The rising prevalence of chronic disorders among the global population is expected to drive market growth throughout the forecast years. The increasing occurrence of chronic illnesses will mostly lead to organ failures. Hence, this issue will probably increase the demand for organ transplant diagnosis provisions. Moreover, the growing adoption of stem cell therapy and customized drugs is gaining a reputation. This is expected to enhance the growth of the transplant diagnosis market undoubtedly.
The major companies that account for the largest transplant diagnostics market share adopt trends such as new product launches with advanced technology for diagnosis and treatment. There has also been a rise in the average income of the global population, which has fueled the healthcare expenditure. Hence, these factors serve as opportunities for global market growth.
There are a few factors that may inhibit the transplant diagnostics market growth. One of the most important is the high cost of the procedures related to the PCR and NGS diagnosis devices. Hence, this may hinder market growth in the long run.
Some factors that may challenge the key transplant diagnosis device providers include the cost of the medical devices. The broadening gap between organ donation and transplantation procedures is an important challenge for the market players. This time restraint and complication may slow down the transplant diagnostics market growth during the forecast years.
Cumulative Growth Analysis
The transplant diagnostics market is anticipated to grow at high speed in the years to come. The market growth will be owing to the rising incidences of chronic diseases and increasing organ failures across the globe. The growing demands for an effective and non-invasive technique of medical procedures are expected to aid in the expansion of the global market. Conversely, the global market growth may be inhibited by the high expenditures related to PCR and NGS devices.
Value Chain Analysis
The increasing adoption of transplant diagnostics is mainly because of the rising occurrence of chronic diseases across the globe. The conditions subsequently lead to organ failures in people, which call for organ transplantation. The growing funding for the research & development of the transplant diagnostics field will also help strengthen the global market during the forecast period. Moreover, the escalating senior population will likely boost the market value during the transplant diagnostics market forecast. Conversely, the high expenditures related to PCR and NGS devices will probably inhibit the market growth over the forecast period.The companies Immucor, which specializes in transplant compatibility diagnostics, and Pirche AG, which specializes in molecular matching and prediction analysis, have formed a multiyear agreement with the goal of developing Immucor's transplant compatibility diagnostics software. In order to further their partnership, Immucor has decided to invest in Pirche. Through this collaboration, the companies claim their transplant analysis software, Immucor, will be directly and easily integrated with Pirche's T-cell and B-cell epitope-matching prediction algorithms. In addition to providing Immucor's customers with unique access to Pirche scores, the two companies have partnered to provide antibody analysis visualizations that are integrated into Immucor's next-generation analysis tools.
The global transplant diagnostics market is classified into many segments such as screening type, product & service, end-user, and application. Listed below are the transplant diagnosis market segments:
Organ Type (Liver)
The Eurofins group of companies, of which Transplant Genomics is a part, is proud to announce the commercial availability of TruGraf Liver, a blood-based gene expression test that gives guidelines for optimisation of immunosuppressive medication in liver transplant recipients. TruGraf Liver is the first diagnostic tool that utilizes gene expression data, enabled by TGI's patented technology and machine learning, to provide the earliest and most accurate image of immune quiescence for liver transplant recipients.
By Product & Service
Reagents & consumables
Software & services
Commercial service providers
Research Laboratories & Academic Institutes
Hospitals and Transplant Centers
The regional division of the transplant diagnostics market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. Among these regions, North America is expected to rule over the global market over the forecast period (2022 – 2027). This is because of the advancements in the healthcare sector in the region. Moreover, most of the skilled surgeons and advanced transplant technologies belong to the US.
This region will be followed by Europe, with a significant share in the global transplant diagnostics industry. This is because of the rising number of organ transplants, donors, and the government's support in developing the transplant diagnosis market in the region. The UK will grow to be the largest market in Europe over the forecast.
The Asia Pacific region is also anticipated to witness a tremendous market growth rate over the forecast period. This is because the Asia Pacific comprises a large pool of patient population and advanced healthcare infrastructure. Furthermore, emerging nations such as India and China are expected to be the most profitable markets, another important aspect in boosting the regional market.
Also, the growing medical tourism destination in the Asia Pacific region is expected to increase the market considerably throughout the assessment period. The Middle East & Africa and the Latin American areas may also witness moderate market growth over the forecast years.
As of October 2022, the French in vitro diagnostics and life sciences powerhouse Eurobio Scientific will have acquired full ownership of Genome Diagnostics BV in the Netherlands (GenDx). With the funds from the purchase, a new organization will be established to promote transplantation-related scientific inquiry and innovation. Through this purchase, Eurobio Scientific will have access to a portfolio of 100% patented products that are among the most effective in the field of HLA1 diagnostics, which is used to determine whether a donor and recipient are compatible prior to a transplant.
The transplant diagnostics industry is dominated by a few companies that play a vital role in the market growth. These transplant diagnosis companies are called critical companies of the market. They contribute to the largest share of the market profit.
The companies account for the market profits by adopting various transplant diagnostics market trends such as joint ventures, product launches, company expansions, and procurements.
Below are the key companies that offer transplant diagnostics in the global market, with the location of their headquarters:
Becton Dickinson and Company (US.)
Bio-Rad Laboratories Inc. (U.S.)
Illumina Inc. (US.)
Immucor Transplant Diagnostics Inc. (US.)
Thermo Fisher Scientific Inc. (US.)
Affymetrix Inc. (US.)
Linkage Biosciences (US.)
Abbott Laboratories Inc. (US.)
bioMérieux S.A. (France)
QIAGEN NV (Netherlands)
Hoffman-La Roche Ltd. (Switzerland)
Omixon Ltd. (UK.)
In December 2020, Thermo Fisher Scientific, the global key player in serving science, declared that it would boost its reach in the North American and European regions for sterile drug product development and commercial production of critical medicines, vaccines, and therapies.
This report delivers all the information about the global transplant diagnostics market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected transplant diagnostics market outlook.
Middle East & Africa
Rest of the world
|Market Size||USD 7.42 Billion|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product & Service, Screening Type, Organ Type and Application|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Hoffman-La Roche Ltd. (Switzerland), Abbott Laboratories Inc (U.S.), CareDx (U.S.), Becton Dickinson and Company (U.S.), Immucor, Inc. (U.S.), QIAGEN N.V. (Netherlands), GenDx (Netherlands), bioMérieux S.A. (France), Omixon Ltd. (U.K.), Illumina, Inc. (U.S.), Affymetrix, Inc (U.S.), Immucor Transplant Diagnostics, Inc (U.S.), Linkage Biosciences (U.S.)|
|Key Market Opportunities||Rapid Development of Diagnostic Products in Emerging Countries to Offer Significant Opportunity for Expansion|
|Key Market Drivers||Growing Incidence of Organ Failure to Favor the Market|
Global Transplant Diagnostics Market is expected to touch a size of USD 7.42 billion by 2030.
Global Transplant Diagnostics Market can expand at 7.80% CAGR from 2020 to 2030.
Heavy funding to R&D institutes by public-private firms can drive the Global Transplant Diagnostics Market.
Global Transplant Diagnostics Market growth can be impeded due to low awareness of patients.
Reagents & consumables can dominate the product & service segment in the Global Transplant Diagnostics Market.
Hospitals & transplant centers are predicted to be the biggest end-user of the Global Transplant Diagnostics Market.
Bio-Rad Laboratories, Inc., Becton Dickinson and Company, Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann La Roche Ltd., bioMérieux S.A., and Illumina, Inc. are some of the biggest players of the Global Transplant Diagnostics Market.